PDCD1 and polyneuropathy: Each PD‐1 inhibitor demonstrated unique neurological signals: meningoradiculitis associated with nivolumab (IC025: 3.44), cranial neuritis related to pembrolizumab (IC025: 3.85), and polyneuropathy correlated with cemiplimab (IC025: 0.71) (Figure 3d).